With a wealth of recent approvals in the gene therapy space and 850+ active trials, the field is moving fast. However, the complexities in predicting, measuring, and mitigating immune responses in both, animal models and patients, threaten developers with serious safety concerns with these bottlenecks leading to clinical holds.

Decision makers from leading drug developers have expressed that there is little visibility into which contract service providers have the experience and expertise to meet these demands. After extensive research with biopharma leaders, there is a clear lack of belief in the quality of two main services:

1. Assay Development Tools – effective, validated, and quick assay development tools to effectively measure and monitor immunogenicity in a clinical and preclinical capacity
2. Animal Models – appropriate animal models to test and understand immune-related safety and efficacy profiles and improve the translatability of gene therapies when approaching IND-filing and first-in-human trials

Partnering with the Annual Gene Therapy Immunogenicity Summit will bring you face-to-face with 100+ immunology, bioanalytical, toxicology, preclinical, clinical, translational, and scientist leaders in the field, actively seeking networking and collaborating opportunities to overcome industry challenges.

Your brand, your message, and your reputation – all showcased in front of the leading experts in the gene therapy field.